Healthcare
Praxis Precision Medicines, Inc.(PRAX)
Live Price
Offline$282.31
+4.56% today
1Y Change
+517.94%
Window
Jun 23, 2025 โ Jun 16, 2026
- Market Cap
- $6.85B
- Revenue Growth
- -100.0%
- EPS Growth
- -32.0%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 23, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Praxis Precision Medicines, Inc. (PRAX) is a Healthcare stock with a market cap of $6.85B and listed on NASDAQ. The stock last traded around $282.31 and up 517.9% across the available one-year price window (Jun 23, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of -32.0%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS -32.0%, free cash flow -89.1% with operating margin 0.0% and ROIC -37.1%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PRAX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-100.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 1, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -100.0% and EPS is at -32.0%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +5.3% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 1, 2026 | โ | +4.1% | +1.8% | +3.4% |
2026 Feb 19, 2026 | -12.0% | +1.1% | +2.7% | -10.3% |
2025 Nov 5, 2025 | +2.6% | +4.7% | +11.5% | +15.4% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRAX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PRAX Max Drawdown
-36.33%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PRAX and SPY.
Company Overview
Praxis Precision Medicines, Inc.
NASDAQ Global Select
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
- Leadership
- Marcio Silva De'Souza
- IPO Date
- Oct 16, 2020
- Employees
- 116
- Street Address
- 99 High Street
- Mailing
- Boston, MA, 02110
- Region
- Boston, MA, US
- Reporting Currency
- USD
- Investor Line
- 617 300 8460
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 8.3
Growth
- Revenue
- -100.0%
- EPS
- -32.0%
- Free Cash Flow
- -89.1%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -58.7%
- ROIC
- -37.1%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 10.22
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.